BioVie Reports Promising Phase 2 Results for Long COVID Drug Bezisterim

BioVie (NASDAQ: BIVI) reports promising Phase 2 results for bezisterim, its investigational oral therapy targeting the neurological symptoms of Long COVID. According to the company, treatment favored placebo on 21 of 22 endpoints overall, with statistically significant improvements on certain measures among prespecified patient subgroups with a high symptom burden.

The findings will require confirmation in a Phase 3 clinical trial as BioVie continues development of bezisterim and its potential application to neurological symptoms associated with Long COVID.

#BioVie
#BIVI
#Bezisterim
#LongCOVID
#LongCOVIDTreatment
#ClinicalTrials
#Phase2
#Phase3
#Biotech
#Biotechnology
#DrugDevelopment
#Neurology
#NASDAQ
#InvestorNews
#NewToTheStreet